Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Press Releases
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société I-MAB
10/15I MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PU
10/13I-MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PR
10/05I-MAB : and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at th..
PR
10/04I MAB : Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzopa..
PU
10/01I-MAB : Announces Upcoming Participation at October Conferences
PR
09/28I-MAB : Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial..
PR
09/13I-MAB : Added to FTSE ESG Index Series
PR
09/02I-MAB : Added to FTSE Russell Global Equity Index Series
PR
08/31I MAB : Provides Business and Corporate Updates and Reports Financial Results for the Six ..
PU
08/30I-MAB : Announces Upcoming Participation at September Conferences
PR
08/27I MAB : Announces Upcoming Participation at September Conferences
PU
08/20I MAB : Announces Establishment of Environmental, Social and Governance Committee (Form 6-..
PU
08/19I-MAB : Announces Establishment of Environmental, Social and Governance Committee
PR
08/17I-MAB : to Provide Business and Corporate Updates and Report Financial Results for the Six..
PR
08/12I MAB : Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plon..
PU
08/11I-MAB : Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plon..
PR
07/30I MAB : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Trea..
PU
07/30I MAB : Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combina..
PU
07/30I-MAB : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Trea..
PR
07/29I MAB : Announces Authorization of a Renewed Stock Repurchase Program by the Company up to..
PU
07/28I-MAB : Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combina..
PR
07/27I MAB : Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of th..
PU
07/27I MAB : Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of th..
PU
07/09I-MAB : Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through ..
PR
07/01I-MAB : Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
PR
06/30I-MAB : Honored with Top Rankings by Institutional Investor
PR
06/29I-MAB : Announces Upcoming Participation at July Conference
PR
06/25I-MAB : Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus ..
PR
06/25I MAB : Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus ..
PU
06/21I MAB : Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scie..
PU
06/02I-MAB : to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differen..
PR
06/01I MAB : Appoints Ruyi He and Rong Shao to Board of Directors (Form 6-K)
PU
06/01I-MAB : Appoints Ruyi He and Rong Shao to Board of Directors
PR
05/27I-MAB : Announces Upcoming Participation at June Conferences
PR
05/20I MAB : Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab ..
PU
05/18I-MAB : Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab ..
PR
05/13I-MAB : Added to MSCI China Index
PR
04/29I-MAB : Announces Upcoming Participation at May Conferences
PR
04/28I-MAB : Filed 2020 Annual Report on Form 20-F
PR
04/28I MAB : Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
PU
04/26I-MAB : Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
PR
04/14I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American S..
GL
04/06I-MAB : and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody T..
AQ
03/31I-MAB : Announces Upcoming Participation at April Conferences
AQ
03/30I-MAB : and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibo..
AQ
03/29I-MAB : Reports Financial Results for Full Year of 2020 and Provides Business Updates
AQ
03/24I-MAB : to Host 2021 R&D Day
AQ
03/19I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
GL
03/11I-MAB : To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 A..
AQ
03/10I-MAB :  Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
AQ
03/03I-MAB : to Report Financial Results for the Full Year 2020 and Provide Corporate Update on..
PR
02/25I-MAB : Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pe..
PR
02/24I-MAB : Announces Upcoming Participation at March Conferences
PR
02/10I-MAB : Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with ..
PR
02/07I MAB : Proposed Registered Secondary Public Offering of American Depositary Shares by Cer..
PU
02/04I-MAB : Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma M..
PR
01/26MORPHOSYS AG : MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of M..
AQ
01/25I-MAB : and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 i..
PR
2020I-MAB : Announces Upcoming Participation at January Conferences
PR
2020I-MAB : Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in..
PR
2020I MAB : Appoints Leading Immunology and Hematology Experts to its Scientific Advisory Boar..
PU
2020I-MAB : to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemz..
PR
2020I MAB : Anti-C5aR antibody shows promise as immuno-oncology
AQ
2020I-MAB : Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SI..
PR
2020I-MAB : Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal ..
PR
2020AbbVie Reports Third-Quarter 2020 Financial Results
AQ
2020I-MAB : Announces Upcoming Participation at November Conferences
PR
2020I MAB : to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Canc..
PU
2020I-MAB : to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Canc..
PR
2020I-MAB : Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin ..
PR
2020I-MAB : Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Rela..
PR
2020I MAB : MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in ..
AQ
2020I MAB : MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in ..
PR
2020I-MAB : Announces Upcoming Participation at September Conferences
PR
2020ABBVIE : and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncol..
PR
1  2Next
Upcoming event on I-MAB
10/26/21